SOURCE: Wall Street News Alert

Wall Street News Alert

June 19, 2008 08:38 ET

Wall Street News Alert Issues Special Alert on OCOL! June 19, 2008

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL--(Marketwire - June 19, 2008) - Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), GE (NYSE: GE), Google (NASDAQ: GOOG) and Pfizer Inc. (NYSE: PFE).

Having announced last week that it has signed an agreement with a leading cancer center (see below), Oncolin Therapeutics (OTCBB: OCOL), should have investors monitoring the stock closely. Early this morning, the company issued a press release announcing that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) will be presenting its lead cancer technology at this prestigious symposium in Geneva Switzerland in October 2008.

This should be great news for OCOL, as the press release states that targeted initially for brain tumors, this technology is a major breakthrough in inhibiting glycolysis, a process many tumor cells, but not normal cells, require for growth and survival. Inhibition of glycolysis "starves" tumors by blocking their ability to provide the energy needed for survival. The founding scientists have designed a drug that passes through the Blood Brain Barrier (BBB), a protective tissue which prevents most other drugs from entering the brain, where this drug is then retained in brain tumor cells selectively blocking the tumors metabolic machinery. This technology is also applicable to other cancers that are depend on glycolysis for survival such as breast and pancreatic cancers. This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson Cancer Center, the # 1 cancer treatment center in the United State according to U.S. News and World Report.

This symposium, hosted by EORTC, NCI and AACR, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. Understanding the pathways and mechanisms which cause cancer and regulate the biological behavior of tumor cells has lead to the development of numerous new agents and innovative targets for clinical trials. This conference has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development. It will bring together delegates from all over the world igniting a huge exchange of information and promoting and developing global partnerships in translational research. The conference has been developed to ensure the maximum amount of interaction and discussion.

The American Association for Cancer Research (AACR), is a nonprofit scientific society of nearly 27,000 laboratory, translational, and clinical cancer researchers whose mission is to prevent and cure cancer through research, education, and communication.

The National Cancer Institute (NCI), founded in 1971, is the principal government agency in the United States charged with coordinating the national effort against cancer. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.

The European Organization for Research and Treatment of Cancer (EORTC), is an international non-profit research organization created in 1962. The mission of the EORTC is to conduct, develop, coordinate and stimulate translational and clinical research in Europe, and to improve the management of cancer and related problems by increasing the survival and quality of life for patients.

Investors are urged to monitor the progress of the company! Last week the company reported that it has signed a sponsored research agreement with The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston, Texas to support work in the laboratory of Prof. Waldemar Priebe. This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors. The company will have a right to an exclusive license to any new patents derived from this research as the company expands its support of Dr. Priebe's drug discovery and development efforts. This sponsored research will initially focus on evaluation of the selected lead compounds with the goal of identifying a superior inhibitor of glycolysis that potently blocks tumor growth.

Professor Waldemar Priebe is a world renowned scientist who has several drugs in clinical development based on research from his laboratory and works at UTMDACC, which is the world's premier cancer center.

Prior to the latest press release, the stock closed Wednesday at Sixteen cents a share.

For an in-depth profile of Oncolin Therapeutics, visit

GE (NYSE: GE) down 2.2% on 88 million shares traded.

GE is Imagination at Work -- a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and advanced materials, GE serves customers in more than 100 countries and employs more than 300,000 people worldwide.

Google (NASDAQ: GOOG) down 1.2% on 3.3 million shares traded.

Google's innovative search technologies connect millions of people around the world with information every day.

Pfizer Inc. (NYSE: PFE) up 0.2% on 95.4 million shares traded.

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. The company discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.

Market Commentary:

"The average national price of a gallon of gas slipped 0.3 cent overnight to $4.075 a gallon, according to a survey of stations by AAA and the Oil Price Information Service. It was the second straight decline, bringing prices half a cent below their latest record of $4.08 a gallon," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at:

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at or see our services at

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 100 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at and select the "join now" button.

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. For current services performed for Oncolin Therapeutics (OTCBB: OCOL), WSCF has been compensated Ninety Thousand shares of Oncolin Therapeutics, by a third party (Jonathan Camarillo Trust), who is non-affiliated and may hold a significant position in the stock. WSCF holds all of those shares as of this release, but intends to immediately begin selling its shares as this release is being circulated. WSCF has also been previously compensated Twenty Seven Thousand Dollars for coverage of Oncolin Therapeutics (OTCBB: OCOL), previously known as Edgeline Holdings, Inc., by the company, for services provided including dissemination of company information in this release. Prior to the name and symbol change, WSCF was previously compensated for services rendered in 2008 and 2007; the previous compensation can be viewed by looking at a previous WSNA, ELHI press release. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information